Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
November 15 2024 - 4:05PM
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a
clinical-stage biotechnology company developing a new generation of
targeted antitumor virotherapies, today announced the closing of
its previously announced public offering of 4,437,869 shares of
common stock at $1.69 per share for gross proceeds of approximately
$7.5 million.
Ladenburg Thalmann & Co. Inc. acted as the exclusive
placement agent for this offering.
The securities described above public offering were offered
pursuant to registration statements on Form S-3 (File No.
333-282456), which were declared effective by the United States
Securities and Exchange Commission ("SEC") on October 10, 2024. The
offering was made solely by means of a prospectus. A final
prospectus relating to the offering was filed with the SEC on
November 15, 2024, and is available on the SEC's website located
at http://www.sec.gov. Copies of the final prospectus can be
obtained at the SEC's website at http://www.sec.gov or
from Ladenburg Thalmann & Co. Inc. Electronic copies of the
final prospectus relating to the offering may be obtained, when
available, from Ladenburg Thalmann & Co. Inc., 640 Fifth
Avenue, 4th Floor, New York, New York 10019, or by telephone at
(212) 409-2000, or by email at prospectus@ladenburg.com. This
press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel stem cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please
visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “towards,” “would” as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements concerning upcoming key milestones
(including the reporting of interim clinical results and the dosing
of patients), planned clinical trials, and statements relating to
the safety and efficacy of Calidi’s therapeutic candidates in
development. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects and are
subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that Calidi
is not able to raise sufficient capital to support its current and
anticipated clinical trials, the risk that early results of
clinical trials do not necessarily predict final results and that
one or more of the clinical outcomes may materially change
following more comprehensive review of the data, and as more
patient data becomes available, the risk that Calidi may not
receive FDA approval for some or all of its therapeutic candidates.
Other risks and uncertainties are set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking
Statements” in the Company’s Registration Statements filed with the
SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding
prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on
April 15, 2024, and the Company’s periodic reports filed with the
SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed
on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024 and (iv)
Form 10-Q filed on November 12, 2024. These reports may be amended
or supplemented by other reports we file with the SEC from time to
time.
For Investors:
Dave Gentry, CEORedChip Companies,
Inc.1-407-644-4256CLDI@redchip.com
Source: Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Dec 2023 to Dec 2024